AMGN$466.011.15%5.28
After Hours: 466.67+0.66 +0.14%
Amgen Inc (AMGN)
Date: 2026-10-30 16:00O: 470.15H: 475.65L: 465.33C: 466.01Vol: 3.185M
Amgen Inc stock is traded at $466.01, with a volume of 3,185,120. It is up +1.15% in the last 24 hours and up +10.56% over the past month. Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Previous Close:
$460.73
Open:
$470.15
24h Volume:
3,185,120
Relative Volume:
1.25
Market Cap:
$251.94B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
32.41
EPS:
$14.38
Net Cash Flow:
$8.60B
1W Performance:
+6.09%
1M Performance:
+10.56%
6M Performance:
+34.59%
1Y Performance:
+59.59%
1-Day Range:
$465.33$475.65
1-Week Range:
$439.28$475.65
52-Week Range:
$288.00$475.65
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen IncSector
HealthcareIndustry
Drug Manufacturers - GeneralPhone
(805)447-1000Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, USACompare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN Amgen Inc | $466.01 | $251.94B | $37.30B | $7.80B | $8.60B | $14.38 |
 LLY Lilly Eli Co | $1,417.54 | $1.26T | $72.25B | $25.28B | $10.37B | $27.78 |
 JNJ Johnson Johnson | $273.20 | $657.68B | $97.93B | $21.04B | $17.80B | $8.63 |
 ABBV Abbvie Inc | $294.89 | $521.11B | $62.82B | $3.60B | $19.98B | $2.03 |
 MRK Merck Co Inc | $149.52 | $368.89B | $65.51B | $8.93B | $14.12B | $3.55 |
 NVS Novartis Ag Adr | $160.79 | $303.67B | $54.66B | $13.58B | $16.05B | $7.02 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
- Khosla RachnaAug 13 '26SVP, Business Development
- Transaction
- Sale
- Cost
- $416.43
- #Shares
- 1,252
- Value ($)
- 521,365
- #Shares Total
- 6,404
- Khosla RachnaAug 13 '26Officer
- Transaction
- Proposed Sale
- Cost
- $412.76
- #Shares
- 1,252
- Value ($)
- 516,775
- #Shares Total
- 0
- Khosla RachnaAug 11 '26SVP, Business Development
- Transaction
- Sale
- Cost
- $412.57
- #Shares
- 2,000
- Value ($)
- 825,134
- #Shares Total
- 6,404
- Khosla RachnaAug 11 '26Officer
- Transaction
- Proposed Sale
- Cost
- $414.21
- #Shares
- 2,000
- Value ($)
- 828,420
- #Shares Total
- 0
- Derek MillerAug 06 '26Officer
- Transaction
- Proposed Sale
- Cost
- $404.85
- #Shares
- 3,890
- Value ($)
- 1,574,866
- #Shares Total
- 0
- Grygiel Nancy A.Aug 06 '26Officer
- Transaction
- Proposed Sale
- Cost
- $447.17
- #Shares
- 2,670
- Value ($)
- 1,193,940
- #Shares Total
- 0
- Grygiel Nancy A.Aug 06 '26SVP & CCO
- Transaction
- Option Exercise
- Cost
- $177.41
- #Shares
- 2,970
- Value ($)
- 526,906
- #Shares Total
- 9,310
- Miller DerekAug 06 '26SVP, Human Resources
- Transaction
- Option Exercise
- Cost
- $169.56
- #Shares
- 3,890
- Value ($)
- 659,574
- #Shares Total
- 14,531
- Miller DerekAug 06 '26SVP, Human Resources
- Transaction
- Sale
- Cost
- $402.54
- #Shares
- 3,890
- Value ($)
- 1,565,898
- #Shares Total
- 12,462
- Grygiel Nancy A.Aug 06 '26SVP & CCO
- Transaction
- Sale
- Cost
- $402.16
- #Shares
- 2,970
- Value ($)
- 1,194,415
- #Shares Total
- 7,340
